– El Grupo Menarini presenta datos nuevos y ampliados en el Simposio sobre cáncer de mama de San Antonio de 2024 que refuerzan el papel de ORSERDU® (elacestrant) para pacientes con cáncer de mama avanzado o metastásico (mBC) ER+, HER2- La evidencia del mundo real refuerza la eficacia de…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.